论文部分内容阅读
目的观察来曲唑组及去势联合来曲唑治疗组间治疗晚期乳腺癌的疗效及不良反应。方法来曲唑组36例绝经后晚期乳腺癌患者接受来曲唑2.5mg口服,每日1次;去势联合来曲唑治疗组10例绝经前晚期乳腺癌接受去势治疗和来曲唑治疗,部分患者加用局部放疗。结果来曲唑组及去势联合来曲唑组治疗晚期乳腺癌均有较好效果。但来曲唑组较去势联合来曲唑组在平均生存时间(37.1个月对26.1个月)以及两年生存率(94.0%对60.0%)均有优势。结论来曲唑治疗晚期乳腺癌效果较好,药物不良反应轻。绝经前女性通过去势联合来曲唑也可以取得满意效果。
Objective To observe the efficacy and side effects of letrozole and castration combined with letrozole in the treatment of advanced breast cancer. Methods Letrozole 36 patients with advanced postmenopausal breast cancer receiving oral Letrozole 2.5mg once daily; castration combined with letrozole treatment group, 10 cases of premenopausal and advanced breast cancer undergoing castration therapy and letrozole treatment Some patients plus local radiotherapy. Results Letrozole group and castration combined with letrozole treatment of advanced breast cancer have good results. However, the letrozole group had an advantage over the castrated letrozole group in mean survival time (37.1 months vs. 26.1 months) and two-year survival rate (94.0% vs. 60.0%). Conclusion Letrozole is effective in treating advanced breast cancer and has mild adverse drug reactions. Premenopausal women through castration combined letrozole can also be satisfied with the results.